INS and neoplasm: Intermittent fasting interventions (including intermittent energy restriction) have been shown repeatedly to reduce glycemia, improve insulin sensitivity, and reduce whole-body cell proliferation rates in studies of both tumor-free animals and humans (24–29)—suggesting that these approaches target glycemic pathways and have anti-proliferative effects.